[ad_1]
Viking Therapeutics Inc’s shares gained about 15% premarket on Thursday after the company signaled progress on an experimental obesity drug that could accelerate its development timeline.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...